Is Cardiol Therapeutics Inc. (CRDL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 28.2% / 30% | 0.3% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 28.2% / 33% | 0.3% / 33% | N/A | ✓ HALAL |
| MSCI | 0.5% / 33% | 96.0% / 33% | 1.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 28.2% / 33% | 0.3% / 33% | N/A | ✓ HALAL |
| FTSE | 0.5% / 33% | 96.0% / 33% | 1.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -348.0% | |
| Return on Assets (ROA) | -148.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$25M |
| Free Cash Flow | -$25M |
| Total Debt | $158,532 |
| Debt-to-Equity | 1.4 |
| Current Ratio | 3.9 |
| Total Assets | $32M |
Price & Trading
| Last Close | $1.11 |
| 50-Day MA | $1.02 |
| 200-Day MA | $1.11 |
| Avg Volume | 364K |
| Beta | 0.7 |
|
52-Week Range
$0.77
| |
About Cardiol Therapeutics Inc. (CRDL)
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cardiol Therapeutics Inc. (CRDL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cardiol Therapeutics Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cardiol Therapeutics Inc.'s debt ratio?
Cardiol Therapeutics Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.5%.
What are Cardiol Therapeutics Inc.'s key financial metrics?
Cardiol Therapeutics Inc. has a market capitalization of $140M. Return on equity stands at -348.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.